The Surgeon

Nymox Pharma has developed a new drug to more effectively treat prostate enlargement, a common and troublesome affliction of men in mid to later age

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.
(more…)

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology1 support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world’s first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
(more…)